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Objectives: The aim of this health economic
modelling study was to investigate the effect of
irbesartan combined with conventional antihyper-
tensive medications compared to conventional an-
tihypertensive therapy alone on the progression of
nephropathy in patients with hypertension, type 2
diabetes and microalbuminuria in a Swiss setting.
Methods: In simulated patients with hyperten-
sion and type 2 diabetes, treatment of microalbu-
minuria with irbesartan 300 mg daily plus conven-
tional antihypertensive medications was compared
to a control regimen (conventional medications
excluding angiotensin converting enzyme inhib-
itors, other angiotensin-2-receptor antagonist and
dihydropyridine calcium channel blockers). Pro-
gression from microalbuminuria to nephropathy,
doubling of serum creatinine, ESRD, and all-
cause mortality was simulated over a 25-year time
horizon using a published Markov model adapted
to a Swiss setting. Transition probabilities were
based on the Irbesartan in Reduction of Micro-
albuminuria-2 Study, Irbesartan in Diabetic
Nephropathy Trial and other sources. Costs and
clinical outcomes were discounted at 5% annually
according to Swiss guidelines, and a third party
payer perspective was taken.
Results: Treatment with irbesartan was pro-
jected to improve mean life expectancy by 0.57
years compared to conventional antihypertension
treatment (undiscounted 1.22 years). Irbesartan
treatment was associated with cost savings of CHF
21,488 per patient over the 25-year time horizon.
Sensitivity analysis showed that irbesartan therapy
remained dominant to conventional antihyperten-
sion treatment over a range of plausible assump-
tions.
Conclusions: Addition of irbesartan to conven-
tional antihypertension therapy was projected to
improve life expectancy and reduce costs in hyper-
tensive patients with type 2 diabetes and microal-
buminuria in a Swiss setting.
Key words: irbesartan; costs; microalbuminuria;
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End-stage renal disease (ESRD) has a huge
impact on health and represents a substantial bur-
den for healthcare payers. Within the last five years
evidence has been published demonstrating that
type 2 diabetes is the major underlying cause of
ESRD, defined as chronic renal failure requiring
dialysis or renal transplant, in the western world,
with nephropathy developing in approximately
40% of type 2 diabetes patients [1, 2]. In Switzer-
land, it has been estimated that there are around
285000 patients with type 2 diabetes, and approx-
imately 2300 patients receiving renal dialysis [3, 4].
As the incidence of type 2 diabetes continues to in-
crease worldwide and the population ages, the bur-
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den represented by type 2 diabetes and associated
ESRD is likely to continue to grow [5].
In 1998, Lundman and Engstrom published
evidence of a link between type 2 diabetes, hyper-
tension and nephropathy [6]. In a Swedish cohort
of type 2 diabetes patients, 50% had concurrent
hypertension and 13% had signs of nephropathy.
Encouragingly, recent studies have reported blood
pressure-independent renoprotective effects of
angiotensin receptor antagonist treatment on the
progression of various stages of renal disease in pa-
tients with hypertension and type 2 diabetes [7–9].
Data from these studies suggest that timely treat-
ment of nephropathy and hypertension in patients
with type 2 diabetes may help to reduce the health
and economic burden of renal failure.
Irbesartan is an angiotensin-2-receptor antag-
onist for the treatment of hypertension that has
been shown to have additional blood pressure in-
dependent renoprotective effects [7, 8]. In 2001,
Parving et al. reported results from the Irbesartan
in Reduction of Microalbuminuria-2 (IRMA-2)
study, which demonstrated that in an international
cohort of 590 patients with type 2 diabetes and
microalbuminuria, treatment with irbesartan was
associated with protection against the progression
from microalbuminuria to overt nephropathy, in-
dependently of its blood pressure lowering effect
[7]. The international Irbesartan in Diabetic
Nephropathy Trial (IDNT) [8], published in the
same year, showed that irbesartan was renoprotec-
tive in a cohort of 1715 patients with hypertension,
type 2 diabetes and advanced overt nephropathy,
reducing the incidence of doubling serum creati-
nine (DSC) and onset of ESRD. These studies
have shown that appropriate treatment can delay
the progression of renal complications in patients
with type 2 diabetes, a fact which could have sub-
stantial benefits in terms of improving life ex-
pectancy and reducing health care costs. 
We have performed a cost-consequence analy-
sis using a decision analytic cost-effectiveness
model to investigate the effect of irbesartan treat-
ment versus conventional blood pressure control
in patients with type 2 diabetes and microalbumin-
uria in the Swiss setting. A peer-reviewed, previ-
ously published computer simulation model was
adapted to project the progression to ESRD, im-
pact on life expectancy and associated costs over
the long-term (25 years), based on data from the
IDNT and IRMA-2 studies [10].
Methods
Model structure
The structure of the model used in the present analy-
sis has been previously published and described in detail
by Palmer et al. [10]. In summary, it is a computer simu-
lation Markov model developed using DATA Pro software
(TreeAge Software Inc., Williamstown, Massachusetts,
USA). The Markov structure is made up of seven disease
states designed to simulate the progression of renal dis-
ease in patients with type 2 diabetes. It models progres-
sion from microalbuminuria (urinary albumin excretion
(UAE) 20–199 µg/min) to early overt nephropathy (UAE
200 µg/min to median UAE 1,900 mg/24 h); advanced overt
nephropathy (median UAE on entry ≥1,900 mg/24 h);
doubling of serum creatinine (DSC); ESRD treated with
dialysis; ESRD treated with renal transplant; and Death as
outlined in figure 1. For the purposes of continuity in the
model, a distinction was made between early and advanced
overt nephropathy to compensate for the differences be-
tween patients reaching the endpoint of the IRMA-2 study
(UAE 200 µg/min with minimum of 30% increase in UAE
from baseline) [7], and those included in the IDNT (me-
dian UAE 1,900 mg/24h) [8]. A deterministic approach
was used, taking point estimates of probabilities and costs
to calculate mean values for the outcomes generated by
the model.
Transition probabilities
Data from the IRMA-2 study were used to calculate
transition probabilities for progression from microalbu-
minuria to early overt nephropathy in the model and have
been previously published [10]. Annual probabilities for
the progression from early overt nephropathy to advanced
overt nephropathy were calculated using linear extrapola-
tion of the rate of increase of UAE in all patients in the
IRMA-2 trial reaching the endpoint (UAE >200 µg/min
with minimum 30% increase from baseline), and evaluat-
ing the conditional probability of reaching the threshold
for entry into the IDNT (advanced overt nephropathy)
stage of the model. A UAE rate of 1,100 mg/24 h was set
as a threshold value to reproduce the baseline character-
istics of the IDNT population. Using this value, the me-
dian UAE of patients crossing this threshold at any given
time corresponded to the median baseline value in IDNT
(UAE 1,900 mg/24 h) [8]. As there were no suitable pub-
lished data on the progression from early to advanced
overt nephropathy, it was conservatively assumed that the
rate of progression from early overt nephropathy to advanced
overt nephropathy in the model was the same in both treat-
ment arms. After the development of ESRD, subsequent
transitions (to account for mortality and changing be-
tween the states representing kidney transplantation and
modes of renal replacement therapy) were also assumed to
be independent of treatment arm. As no data for these
transitions were available for the Swiss setting, data from
Germany were used as a substitute. The published data re-
ported that 0.35% of patients diagnosed with ESRD re-
ceived renal transplantation [11]. Approximately 95.2% of
patients start haemodialysis and 4.8% receive peritoneal
dialysis [11]. The proportion of patients receiving other
forms of dialysis (such as autodialysis or home haemodial-
ysis) was considered negligible. Although these figures
refer specifically to the global population of ESRD
patients, they are likely to be similar for patients with
diabetes mellitus.
Transition probabilities for the switch from dialysis
to transplantation were based on German data from the
year 2000, which showed an annual rate of 4.2% for dial-
ysis patients receiving transplants [11]. This rate refers to
all dialysis patients, but no data have been published for
patients with diabetes alone. The fact that the dialysis
patients with type 2 diabetes are older and have a higher
mortality rate than the average dialysis patients suggest
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that these transition probabilities may differ, but literature
search revealed no published information on the effect of
duration of dialysis on the transition from dialysis to trans-
plantation. Therefore the same transition probability has
been used in each cycle of the model, even though it is gen-
erally accepted that transplant rates increase with duration
of dialysis. Calculation of probabilities for the transition
from transplant to dialysis was based on data from the Eu-
ropean transplant register which reported the transplant
to dialysis as 17.1% in the first year decreasing to 5% in
subsequent years [12].
Figure 1
Model Structure.
The diagram illustrates the progression
of simulated patients in the model.
Squares represent decision nodes (in
this case for treatment) which can be
defined by the user. Circles with the 
letter ‘M’ in the middle indicate Markov
nodes in the model, which outline typi-
cal progression from top (MA) to bot-
tom (Dead) states as represented in the
diagram. Green circles represent
chance nodes which allow “possible”
events to occur during the simulation.
Red triangles with a state description
afterwards indicate where patients will
be sent at each cycle end. The structure
is shown for irbesartan. [+] indicates
same tree structure but with different
transition probabilities for control.
MA = microalbuminuria; 
DSC = doubling of serum creatinine;
ESRD = end-stage renal disease.
Treatment Annual costs (CHF) Reference(s)
Year 1 Years 2+
Renal transplant 95,000 25,000 [19] 
Dialysis 71,000 71,000 [20] 
Control Irbesartan
Life expectancy (years) 14.39 15.61
[undiscounted / discounted at 5% p.a.]
Life years gained versus control (years), undiscounted – 1.22
Life expectancy (years), discounted at 5% p.a.] 9.80 10.37
Life years gained versus control (years), discounted at 5% p.a. – 0.57
Years free of ESRD* 12.90 15.04
Cumulative incidence of ESRD (%) 26.6 10.7
25-year costs** (CHF) 46,956 25,469
Cost savings versus control – 21,487
* = mean outcome per patient; ** costs discounted at 5% p.a.; Control = conventional antihypertensive
medications excluding ACE-Is, other angiotensin-2-receptor antagonists and dihydropyridine calcium 
channel blockers with equivalent blood pressure control.
Table 1
Costs of ESRD treat-
ment in Switzerland.
Table 2
Summary of results.
Mortality calculations
In the states of microalbuminuria, early overt nephro-
pathy, advanced overt nephropathy, and DSC, mortality was
calculated using age- and gender-specific all-cause mortal-
ity tables and values adjusted by state-dependent RRs.
Mortality was independent of treatment arm and was de-
pendent on the level of renal disease reached by a simu-
lated patient. In the state microalbuminuria the RR for all-
cause mortality was based on data from the Danish Steno-
2 study versus age- and gender-matched mortality in the
general Danish population [13, 14]. RR of mortality for
patients with type 2 diabetes, hypertension and microal-
buminuria was calculated to be 2.03. The RR of mortality
in both overt nephropathy states was calculated in a simi-
lar way based on data published by Stehouwer et al. [15].
The RR for mortality in patients with type 2 diabetes, hy-
pertension and overt nephropathy was calculated to be 4.4
compared to the general population. In the absence of
published data, RRs for all-cause mortality in the early
live – no progression – stay in “MA”
MA
early overt nephropathy
late overt nephropathy
DSC
Dialysis
Transplant
Dead
Control
Irbesartan
Select treatment for MA
progress to “early overt nephropathy”
die
die
die
live – no progression – stay in “early overt nephropathy”
progression to “late overt nephropathy
progress to “DSC”
live – no progression – stay in “late overt nephropathy
develop ESRD
treat initially with dialysis
treat initially with transplant
treat initially with dialysis
treat initially with transplant
Dialysie
MA
early overt nephropathy
Dead
Dead
DSC
Dead
Dead
Dialysis
Dialysis
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Transplant
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Dead
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Transplant
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stay in “Dialysis”
receive transplant
die
viable graft – stay in “Transplant”
tranfer to “Dialysis”
die
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overt nephropathy, advanced overt nephropathy and DSC
states were conservatively assumed to be the same. In the
ESRD state, mortality was dependent on the type of renal
replacement therapy received (i.e. dialysis or transplanta-
tion). Annual mortality in dialysis patients in Switzerland
was 16.91% [16]. For transplant patients, mortality was
calculated based on data from the European transplant
register [12]. Comparable mortality rates have been re-
ported in two other recent publications [17, 18].
Simulated cohort and treatments
The model simulated a hypothetical cohort with type
2 diabetes, hypertension and microalbuminuria (UAE 20–
199 µg/min on two out of three consecutive occasions),
with characteristics similar to those of the baseline cohort
of the IRMA-2 study [7]. The simulated cohort was treated
with either irbesartan 300 mg daily plus conventional an-
tihypertensive therapy (irbesartan group), or conventional
antihypertensive treatment alone (including diuretics,
beta blockers, alpha/beta blockers, peripheral vasodilators,
peripheral adrenergic blockers, and central adrenergic
blockers, but excluding angiotensin converting enzyme
inhibitors [ACE-I], other angiotensin-2-receptor antago-
-
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Figure 2
Number of life years
gained per 1000 pa-
tients treated with
irbesartan versus
control.
0
20
40
60
80
100
120
140
160
180
0 5 10 15 20 25
Years since Baseline Age of 58
Ca
s
e
s
 o
f E
SR
D
 
A
v
o
id
e
d
Pe
r 
10
00
 P
a
tie
n
ts
 
Tr
e
a
te
d
Irbesartan vs.
Control
-4'000'000
0
4'000'000
8'000'000
12'000'000
16'000'000
20'000'000
24'000'000
0 5 10 15 20 25
Years since Baseline Age of 58
Co
st
 
Sa
v
in
gs
Pe
r 
10
00
 P
at
ie
n
ts
 
Tr
ea
te
d
(C
HF
) Cost savings,Irbesartan vs.
Control
Figure 3
Number of ESRD
cases avoided per
1000 patients treated
with irbesartan ver-
sus control.
Figure 4
Cost savings over
time per 1000 pa-
tients treated for
irbesartan versus
control.
Undiscounted life expectancy (years) 25-year costs* (CHF)
Control Irbesartan Control Irbesartan
Base case 14.39 15.61 46,866 25,505
UAE threshold for advanced over nephropathy set 14.31 15.59 54,242 28,391
to 585 mg/24 h
UKPDS mortality data for no renal disease, 15.17 16.56 50,698 27,458
microalbuminuria, or overt nephropathy
RR of mortality in the states leading up to ESRD set  18.65 19.61 67,487 35,898
to 1.0, simulating only effects of treatment on delaying 
ESRD onset ESRD and associated mortality
* costs discounted at 5% p.a.; Control = conventional antihypertensive medications excluding ACE-Is, 
other angiotensin-2-receptor antagonists and dihydropyridine calcium channel blockers with equivalent blood pressure control.
Table 3
Sensitivity analysis.
nists and dihydropyridine calcium channel blockers) to
achieve a target blood pressure of <135/85 mm Hg, and
started when patients were in the state of microalbumin-
uria. In both treatment groups, therapy was initiated when
patients had developed microalbuminuria.
Costs
All the costs retrieved have been updated to 2003 val-
ues according to the consumer price index, and are re-
ported as 2003 Swiss Francs (CHF). The perspective of a
third party Swiss health insurance payer was taken. The
analysis focused on the incremental costs of the addition
of irbesartan to otherwise conventional blood pressure
control, and on the costs associated with the treatment of
ESRD in the simulated cohort. The annual costs of irbe-
sartan 300 mg daily were CHF 788 per patient. Regard-
ing the costs of other medications, it was assumed that
these did not differ between treatment groups, and were
therefore not included in the present analysis. It could be
argued that this was a conservative assumption which per-
haps biases the study against the irbesartan treatment arm,
given that the cost of conventional antihypertensive ther-
apy in the control group is not included in the analysis.
Costs of ESRD, dialysis or transplant were included
as previously reported for Switzerland (table 1) [19, 20].
Cost estimates for renal transplant and follow-up treat-
ment due to ESRD were estimated based on national in-
surance data [19]. The cost of transplantation in the first
year was derived by calculating a weighted average de-
termined by the number of patients who received either 
a cadaveric or living donor transplant. The unit cost of
haemodialysis was based on the Schweizerischer Dialyse-
tarifvertrag and the cost of peritoneal dialysis was calcu-
lated using data reported in the literature and expert in-
terviews, as exact figures were not available elsewhere
[19–21].
Sensitivity analysis
To assess the robustness of the study findings, several
sensitivity analyses were performed. One such analysis was
on the level of UAE at which patients would enter the
IDNT part of the model (i.e. the advanced overt nephropa-
thy state). In the base-case analysis, median UAE for those
patients who progressed to advanced overt nephropathy
was 1900 mg/24 h, using a threshold of 1100 mg/24 h for
entering the IDNT state, chosen to reflect the baseline
characteristics of patients in the IDNT study [8]. We
tested the effect of changing the threshold value to 585
mg/24 h (the minimum UAE required for inclusion in the
IDNT) on projected costs and life expectancy. Sensitivity
analysis was also performed on assumptions of annual
mortality rates in the model. The annual probabilities of
dying for the newly-diagnosed patients with type 2 dia-
betes and either no renal disease, microalbuminuria, or
overt nephropathy have recently been assessed in the
United Kingdom; these were 1.4%, 3.0%, and 4.6%
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respectively [22]. These values were applied as constant
age- and gender-independent mortality rates to assess the
impact on costs and life expectancy. An additional sensi-
tivity analysis was performed by varying the RR of mor-
tality in the states leading up to ESRD by setting them to
a value of 1.0. As such, the model only simulated the ef-
fects of treatment on delaying the onset of ESRD and its
associated increase in mortality.
Results
Life expectancy
Irbesartan treatment was associated with im-
provements in life expectancy compared to con-
ventional antihypertension treatment (table 2).
Mean discounted (5% per annum) life expectancy
was 10.37 years in the irbesartan group and 9.80
years in the control group, corresponding to an
incremental gain in discounted life expectancy of
0.57 years with irbesartan. Undiscounted life ex-
pectancy in the irbesartan treatment group was
15.61 years compared to 14.39 years with control.
Irbesartan was associated with an improvement in
undiscounted life expectancy of 1.22 years versus
control. Analysis of life years saved with irbesartan
versus control indicated that the benefits in terms
of survival could be observed after 7 years of irbe-
sartan treatment (figure 2). 
Cumulative incidence and years free of ESRD
The cumulative incidence of ESRD after 25
years was 10.7% in the irbesartan group compared
to 26.6% in the control group (table 2). Plotting
the number of cases of ESRD avoided with irbe-
sartan treatment versus control showed that after
3–4 years of simulation, cases of ESRD avoided
were evident for irbesartan versus control (figure
3). After 10 years of the simulation, more than 60
cases of ESRD per 1000 patients were avoided with
irbesartan versus control. Irbesartan was estimated
to delay the onset of ESRD by a mean of 2.14 years,
corresponding to 255 fewer days of ESRD treat-
ment compared to conventional antihypertension
treatment.
Costs
Irbesartan treatment was associated with cost
savings of CHF 21,487 per patient compared to
conventional antihypertension treatment over the
25-year simulation. Projected costs per patient,
discounted at 5% per annum were CHF 25,469
with irbesartan treatment and CHF 46,956 in the
control treatment group. Analysis of cost savings
with irbesartan versus control showed that over the
first 8-9 years of treatment, irbesartan was more
expensive than control, but cost savings became
evident after around 10 years of treatment (figure
4).
Sensitivity analysis
Variation in the UAE rate threshold values for
patients entering the state of advanced overt
nephropathy in the model (i.e. entering the IDNT
portion of the model) had no effect on the relative
outcomes. With the threshold value set to the min-
imum (UAE of 585 mg/24 h) inclusion level for the
IDNT, irbesartan treatment was projected to be
both cost- and life-saving compared to control.
Undiscounted life expectancy was 1.3 years greater
with irbesartan than with control and irbesartan
was associated with cost savings of over CHF
25,000 (table 3).
When the impact of using different assump-
tions on the annual probability of dying in the
states of microalbuminuria, early overt nephropathy,
and advanced overt nephropathy was assessed, the
relative results remained stable under all condi-
tions tested. When UKPDS-derived constant age-
and gender-independent annual mortality rates for
the state-specific mortality rates were applied
(3.0% in microalbuminuria, and 4.6% in early and
advanced overt nephropathy and DSC), treatment
with irbesartan still improved undiscounted life ex-
pectancy by 1.22 years versus control treatment
and reduced 25-year costs by approximately CHF
19,700 (table 3).
When only the effects of treatment on delay-
ing the onset of ESRD and its associated increase
in mortality were assessed by setting the RR of
mortality in the states microalbuminuria, early overt
nephropathy, advanced overt nephropathy and DSC to
1.0, treatment with irbesartan led to incremental
cost savings of approximately CHF 31,588 and an
improvement in undiscounted life expectancy of
0.96 years compared to control (table 3). 
Discussion
Treatment with irbesartan in hypertensive
type 2 diabetes patients with microalbuminuria
was projected to extend life and reduce costs when
compared to conventional antihypertension treat-
ment. Given the substantial burden associated with
ESRD, the most common underlying cause of
which is type 2 diabetes, these data suggest that
irbesartan represents an attractive treatment op-
tion in patients with hypertension and type 2 dia-
betes in Switzerland. Sensitivity analysis demon-
strated that these findings were robust under vari-
ation in a range of assumptions, including mortal-
ity rates. Setting the RR of mortality in the states
leading up to ESRD to 1.0, to produce results that
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only reflect the impact of treatment on onset of
ESRD and associated mortality, had the greatest
impact on the absolute values of undiscounted life
expectancy and 25-year costs, but had no impact
on the relative results (i.e. treatment with irbesar-
tan resulted in reduced costs and was life-saving).
The RRs of mortality in the base case analysis were
2.03 for patients in the microalbuminuria state
(based on the Steno-2 trial [13], and supported by
data from the UK [23]) and 4.4 in the overt
nephropathy and DSC states (based on Stehouwer
et al.) [15]. When these values were replaced with
RRs values derived from the UKPDS, the relative
results also remained unchanged, with irbesartan
treatment started in the state of microalbuminuria
leading to life- and cost-savings in comparison to
control.
It is worthy of note that only the incremental
costs of irbesartan and ESRD treatment were in-
cluded in the present study. This could be consid-
ered a conservative approach, as the non-inclusion
of the costs of concomitant conventional antihy-
pertensive therapy should bias against irbesartan.
However, it is unlikely that this would be a major
driver of overall costs in this population. Previ-
ously published data indicates that “other costs”,
such as those associated with additional concomi-
tant medications and cardiovascular disease events,
only have a relatively small impact compared to the
costs of developing ESRD on total costs in patients
with overt nephropathy [24].
The model used in the analysis has been vali-
dated by comparing results generated from the
model to results of the IDNT and IRMA-2 stud-
ies, with a close correlation noted between ob-
served and predicted results.
Perhaps the primary limitation of the analysis
was that, due to the lack of direct clinical compar-
isons, we were unable to compare the projections
for irbesartan treatment with those of ACE-Is or
other angiotensin-2-receptor antagonists. In the
IRMA-2 and IDNT studies, the control arms in-
cluded commonly used antihypertensive treat-
ment like diuretics, beta blockers, calcium channel
blockers (except dihydropyridines) and central
alpha antagonists to achieve the target blood pres-
sure of <135/85 mm Hg, but excluded ACE-Is and
angiotensin receptor blockers [7, 8]. It currently
remains unclear whether ACE-Is are associated
with renoprotective effects, i.e. a beneficial effect
of ACE-Is on kidney function beyond blood pres-
sure control in hypertensive patients with type 2
diabetes and microalbuminuria, since the nine
published studies to date have provided conflicting
evidence [25–32]. So far, one very recent study did
not find a difference between the angiotensin re-
ceptor blocker telmisartan and the ACE inhibitor
enalapril with respect to change in glomerular fil-
tration rate, urinary albumin excretion and blood
pressure in type 2 diabetics with nephropathy [33].
Interestingly, modeling studies have shown that
treatment of nephropathy with ACE-Is in patients
with type 1 diabetes and non-diabetic nephropa-
thy in a number of different countries may lead to
long-term cost savings [34–39]. Future head-to-
head clinical studies comparing ACE-Is and an-
giotensin-2-receptor antagonists would provide
valuable data, not least in facilitating health eco-
nomic comparisons between the two.
One may question the generalisability of re-
sults of an intervention taken from a clinical trial
and translated into a “real life” setting. It is usually
assumed that effectiveness of an intervention will
be lower in a real-life population compared to ef-
ficacy observed in a clinical trial, primarily due to
factors such as lower adherence to- or compliance
with medications. This may have an impact on the
cost-effectiveness of an intervention outside the
clinical trial setting, with decreased costs of med-
ications and a lesser clinical impact of the interven-
tion due to lower adherence. If results of studies in
a non-clinical trial setting (e.g. post-marketing/
phase 4 studies) become available which more
closely reflect the effectiveness of irbesartan, it will
be interesting to feed these results into the cost-
effectiveness model and observe the impact on
projected long term costs and clinical outcomes.
Another limitation of this analysis is the lack
of published data regarding the distribution of
treatment of ESRD with hemodialysis, CAPD or
transplant in Switzerland, which meant that we
had to use German data as a substitute in this
analysis. This highlights an area of limited research
in Switzerland - data of this nature would be wel-
come in the Swiss setting.
Conclusions
In the majority of cases, advances in technol-
ogy leading to improvements in healthcare are as-
sociated with increased costs. Limited budgets
mean that healthcare payers are often faced with
difficult decisions when selecting which interven-
tions to fund. The findings of this health economic
analysis indicate that irbesartan treatment of type
2 diabetes patients with hypertension and microal-
buminuria is both cost- and life-saving in the Swiss
setting. These data suggest that use of irbesartan
will not only improve outcomes in this patient
population, but will result in cost savings to health-
care payers in Switzerland.
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